These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15566328)

  • 21. Gatifloxacin in community-acquired respiratory tract infection.
    Sethi S
    Expert Opin Pharmacother; 2003 Oct; 4(10):1847-55. PubMed ID: 14521494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemifloxacin: survival of the fittest.
    Mandell L
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():33-7. PubMed ID: 10997597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial treatment of lower respiratory tract infections in the hospital setting.
    Grossman RF; Rotschafer JC; Tan JS
    Am J Med; 2005 Jul; 118 Suppl 7A():29S-38S. PubMed ID: 15993675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.
    Zhanel GG; Fontaine S; Adam H; Schurek K; Mayer M; Noreddin AM; Gin AS; Rubinstein E; Hoban DJ
    Treat Respir Med; 2006; 5(6):437-65. PubMed ID: 17154673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.
    Marchese A; Debbia EA; Schito GC
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():11-5. PubMed ID: 10997594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice.
    Bast DJ; Dresser L; Duncan CL; Walker SE; Mandell LA; Low DE; de Azavedo JC
    J Chemother; 2006 Dec; 18(6):634-40. PubMed ID: 17267342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moxifloxacin: a respiratory fluoroquinolone.
    Miravitlles M; Anzueto A
    Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
    Hammerschlag MR
    J Antimicrob Chemother; 2001 Nov; 48(5):735. PubMed ID: 11679567
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection.
    Berry V; Page R; Satterfield J; Singley C; Straub R; Woodnutt G
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():79-85. PubMed ID: 10824037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.
    Shams WE; Evans ME
    Drugs; 2005; 65(7):949-91. PubMed ID: 15892589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.
    Léophonte P; File T; Feldman C
    Respir Med; 2004 Aug; 98(8):708-20. PubMed ID: 15303634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.
    Koeth LM; Jacobs MR; Bajaksouzian S; Zilles A; Lin G; Appelbaum PC
    Int J Antimicrob Agents; 2002 Jan; 19(1):33-7. PubMed ID: 11814765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemifloxacin (factive).
    Med Lett Drugs Ther; 2004 Sep; 46(1192):78-9. PubMed ID: 15452464
    [No Abstract]   [Full Text] [Related]  

  • 37. Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae.
    Owens RC; Bhavnani SM; Ambrose PG
    Diagn Microbiol Infect Dis; 2005 Jan; 51(1):45-9. PubMed ID: 15629228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of gemifloxacin: results from the GLOBE study.
    Halpern MT; Palmer CS; Zodet M; Kirsch J
    Am J Health Syst Pharm; 2002 Jul; 59(14):1357-65. PubMed ID: 12132563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections.
    Ball P; File TM; Twynholm M; Henkel T
    Int J Antimicrob Agents; 2001 Jul; 18(1):19-27. PubMed ID: 11463522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?
    Balter M; Weiss K
    Can Fam Physician; 2006 Oct; 52(10):1236-42. PubMed ID: 17279183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.